From: The hippo signaling pathway: implications for heart regeneration and disease
Mouse line | Cardiac phenotype | Yap activity | References |
---|---|---|---|
Mst1 Tg (αMHC) | Dilated cardiomyopathy, increased apoptosis and no compensatory hypertrophy. Premature death. | ND | [129] |
DN-Mst1 Tg (αMHC) | Normal cardiac function. Protection against I/R and MI. | ND | |
Lats2 Tg (αMHC) | Baseline cardiac dysfunction. Reduced heart size. | ND | [135] |
DN-Lats2 Tg (αMHC) | Cardiac hypertrophy with normal cardiac function. Protection against I/R. | ND | [135] |
Sav1 cKO (Nkx2.5-cre) | Embryonic lethal. Cardiomegaly, thickened walls and increased proliferation. | Increased | [60] |
Mst1/2 cKO (Nkx2.5-cre) | Embryonic lethal. Enlarged heart. | ND | [60] |
Lats1/2 cKO (Nkx2.5-cre) | Embryonic lethal. Enlarged heart. | ND | [60] |
Yap Tg (αMHC) | Enlarged heart with increased proliferation. Increased cardiac regeneration. | Increased | [123] |
Yap Tg (αMHC) | Enlarged heart with Increased proliferation. | Increased | [115] |
Yap Tg (αMHC; ROSA26fs-rtTA; TRE-Yap) | Normal cardiac function. Increased proliferation. Protection against MI with no change in apoptosis. | Increased | [124] |
Yap cKO (Nkx2.5-cre) | Embryonic lethal. Reduced heart size, reduced proliferation. | Reduced | |
Yap cKO (Tnnt2-cre) | Embryonic lethal. Reduced heart size, reduced proliferation. | Reduced | [115] |
Yap cKO (αMHC-cre) | Dilated cardiomyopathy, increased apoptosis, increased fibrosis and premature death. Worsened outcome after MI (het). | Reduced | |
Sav1 cKO (αMHC-MCM) | Normal cardiac function. Increased proliferation and heart regeneration. Protected against MI. | Increased | [125] |
Lats1/2 cKO (αMHC-MCM) | Normal cardiac function. Increased proliferation and heart regeneration. Protected against MI. | Increased | [125] |